Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2
Holwerda, M.; V'kovski, P.; Wider, M.; Thiel, V.; Dijkman, R.
Show abstract
With currently over 4 million confirmed cases worldwide, including more than 300000 deaths, the current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has a major impact on the economy and health care system. Currently, a limited amount of prophylactic or therapeutic intervention options are available against SARS-CoV-2. In this study, we screened 400 compounds from the antimicrobial Pandemic Response Box library for inhibiting properties against SARS-CoV-2. We identified sixteen compounds that potently inhibited SARS-CoV-2 replication, of which five compounds displayed equal or even higher antiviral activity compared to Remdesivir. These results show that five compounds should be further investigated for their mode of action, safety and efficacy against SARS-CoV-2. HighlightsO_LI400 compounds from the pandemic response box were tested for antiviral activity against SARS-CoV-2. C_LIO_LI5 compounds had an equal or higher antiviral efficacy towards SARS-CoV-2, compared to the nucleoside analogue Remdesivir. C_LI
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors 97%
- Identification of novel Ebola virus inhibitors using biologically contained virus 97%
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. 96%
Similar papers in this journal
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs 98%
- Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro 96%
- Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production 95%
Similar papers in this journal
Similar papers in this journal
- Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells 97%
- Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro 97%
- The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.